Polycystic ovary syndrome (PCOS) is defined by two of three criteria (Rotterdam criteria): irregular or absent ovulation, clinical or biochemical hyperandrogenism (excess testosterone, hirsutism, acne), and polycystic ovarian morphology on ultrasound. The name is somewhat misleading — not all women with PCOS have polycystic ovaries, and "cysts" are actually follicles. The unifying mechanism in most phenotypes is hyperinsulinemia and insulin resistance: elevated insulin stimulates the ovarian theca cells to produce excess androgens, which disrupt follicular development, impair ovulation, and create the hormonal environment that perpetuates the syndrome.
GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide) directly address insulin resistance through multiple mechanisms: they reduce postprandial insulin secretion, increase insulin sensitivity, reduce appetite and body weight (adipose tissue drives insulin resistance), and have direct effects on hypothalamic-pituitary signaling. In women with PCOS, this represents an attack on the root pathophysiology — not just symptom management.
Jensterle et al. 2015 (J Clin Endocrinol Metab, N=32, liraglutide 1.2mg vs. metformin vs. combination × 12 weeks): All three groups showed significant reductions in testosterone and LH:FSH ratio. The liraglutide group had greater weight loss (−4.8kg vs. −3.7kg metformin). Menstrual cycle regularity improved in all groups; liraglutide + metformin combination produced the greatest improvement.
Nylander et al. 2017 (Hum Reprod, N=40, liraglutide 1.8mg × 24 weeks): Significant reductions in BMI, testosterone, and LH levels. Menstrual frequency increased from ~4 cycles/year to ~7 cycles/year in the treatment group. HbA1c and HOMA-IR (insulin resistance marker) both improved significantly. No significant effect on AMH (anti-Müllerian hormone, ovarian reserve marker).
Cena et al. 2023 (EJOG, N=50, semaglutide 0.5–1mg/week × 24 weeks): Mean body weight reduction −9.2kg. Testosterone reduced significantly (−28% from baseline). Menstrual cycle regularity improved in 68% of participants with prior oligomenorrhea. HOMA-IR improved by 42%. First semaglutide-specific PCOS pilot RCT; limitations include small size and no placebo comparator arm.
Real-world data 2024 (retrospective, N=187 women with PCOS on semaglutide or tirzepatide): 71% reported improvement in menstrual regularity; 23% of previously anovulatory women reported spontaneous ovulation during treatment. These are observational, not randomized, but reflect what clinicians are seeing at scale.
Important caveat for fertility planning: GLP-1 agonists are not recommended during pregnancy. The restoration of ovulation creates unintended pregnancy risk in women not using contraception. Adequate contraception during treatment is essential if pregnancy is not the immediate goal.
| Outcome | Evidence for Improvement | Mechanism |
|---|---|---|
| Body weight | Very strong — GLP-1 primary effect; −5–15% depending on dose and duration | Appetite suppression + reduced caloric intake |
| Insulin resistance (HOMA-IR) | Very strong | Direct GLP-1R signaling + weight-loss-mediated insulin sensitization |
| Free testosterone | Strong — consistent across liraglutide and semaglutide trials | Reduced insulin → reduced ovarian androgen production |
| Menstrual cycle regularity | Moderate-Strong — 60–70% of women with oligomenorrhea show improvement | Androgen normalization + weight loss restoring HPO axis function |
| LH:FSH ratio | Moderate — normalizes in most trials | Reduced insulin's amplification of LH pulsatility |
| Hirsutism and acne | Moderate — improves with androgen reduction, but slowly (3–6 months) | Androgen normalization; hair follicle response is slow |
| Spontaneous ovulation rate | Moderate — significant in those who lose ≥5% body weight | HPO axis restoration; weight-loss threshold effect |
| AMH (ovarian reserve) | Inconsistent — some studies show slight reduction (normalization from elevated levels); no evidence of harm to reserve | Uncertain; may reflect follicular maturation improvement |
GLP-1 agonists restore ovulation in many women with anovulatory PCOS. This creates significant risk of unintended pregnancy. All GLP-1 drugs are contraindicated during pregnancy (animal studies show fetal harm; human data is limited). Women who are not planning immediate pregnancy must use effective contraception throughout treatment. Discuss fertility goals explicitly with the prescribing physician before starting.
If pregnancy is the goal: GLP-1s should be discontinued before attempting conception. The restoration of cycle regularity during treatment is a positive sign of HPO axis recovery, but treatment should be stopped 2 months before attempting pregnancy to allow drug clearance (semaglutide has a 5-week half-life).
Who benefits most: Women with PCOS phenotype A or B (hyperandrogenism + oligoanovulation + polycystic ovaries), BMI >25, insulin resistance confirmed by elevated fasting insulin or HOMA-IR, or prior failed response to metformin. Lean PCOS (normal BMI) patients have less data but may still benefit from insulin-sensitizing effects independent of weight loss.
Combination with metformin: Many endocrinologists combine GLP-1 agonist + metformin in PCOS — complementary mechanisms (GLP-1 reduces postprandial insulin/appetite; metformin reduces hepatic glucose production and improves peripheral insulin sensitivity). The combination shows additive benefit in the Jensterle trial and in clinical practice.
Monitoring: Baseline testosterone (free and total), LH:FSH ratio, fasting insulin, HOMA-IR, HbA1c, menstrual diary. Recheck at 3 and 6 months. Menstrual regularity improvement lags androgen improvement by 4–8 weeks — be patient with cycle data.
Insurance coverage: GLP-1 agonists for PCOS are off-label. Coverage depends on whether the patient also meets criteria for obesity (BMI ≥30 or ≥27 with comorbidity) or type 2 diabetes. Many women with PCOS qualify on weight criteria. Work with a physician to document the appropriate indication.